Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer
Crossref DOI link: https://doi.org/10.1007/s12032-016-0760-x
Published Online: 2016-04-04
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takayama, Tatsuya
Kubo, Taro
Morikawa, Ai
Morita, Tatsuo
Nagano, Osamu
Saya, Hideyuki
Funding for this research was provided by:
the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct)
Text and Data Mining valid from 2016-04-04